Steenhuis, E.G.M.; van Disseldorp, L.M.; Jacobs, F.J.C.; van Schayk, N.; Suijkerbuijk, K.; Louwman, M.; d’Hooghe, J.N.S.; Damhuis, R.A.M.; van Geffen, W.H.
Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study. Cancers 2026, 18, 2019.
https://doi.org/10.3390/cancers18122019
AMA Style
Steenhuis EGM, van Disseldorp LM, Jacobs FJC, van Schayk N, Suijkerbuijk K, Louwman M, d’Hooghe JNS, Damhuis RAM, van Geffen WH.
Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study. Cancers. 2026; 18(12):2019.
https://doi.org/10.3390/cancers18122019
Chicago/Turabian Style
Steenhuis, Eline G. M., Lieke M. van Disseldorp, Femke J. C. Jacobs, Nathalie van Schayk, Karijn Suijkerbuijk, Marieke Louwman, Julia N. S. d’Hooghe, Ronald A. M. Damhuis, and Wouter H. van Geffen.
2026. "Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study" Cancers 18, no. 12: 2019.
https://doi.org/10.3390/cancers18122019
APA Style
Steenhuis, E. G. M., van Disseldorp, L. M., Jacobs, F. J. C., van Schayk, N., Suijkerbuijk, K., Louwman, M., d’Hooghe, J. N. S., Damhuis, R. A. M., & van Geffen, W. H.
(2026). Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study. Cancers, 18(12), 2019.
https://doi.org/10.3390/cancers18122019